IL278366A - - Google Patents
Info
- Publication number
- IL278366A IL278366A IL27836620A IL27836620A IL278366A IL 278366 A IL278366 A IL 278366A IL 27836620 A IL27836620 A IL 27836620A IL 27836620 A IL27836620 A IL 27836620A IL 278366 A IL278366 A IL 278366A
- Authority
- IL
- Israel
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018085217 | 2018-04-29 | ||
| CN2018107134 | 2018-09-21 | ||
| PCT/CN2019/085001 WO2019210828A1 (en) | 2018-04-29 | 2019-04-29 | Bcl-2 INHIBITORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL278366A true IL278366A (https=) | 2020-12-31 |
| IL278366B1 IL278366B1 (en) | 2025-05-01 |
| IL278366B2 IL278366B2 (en) | 2025-09-01 |
Family
ID=68386968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL278366A IL278366B2 (en) | 2018-04-29 | 2019-04-29 | BCL-2 inhibitors |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11420968B2 (https=) |
| EP (2) | EP3788042B1 (https=) |
| JP (4) | JP2021521138A (https=) |
| KR (1) | KR102738032B1 (https=) |
| CN (3) | CN117683029A (https=) |
| AU (1) | AU2019264475C1 (https=) |
| BR (1) | BR112020022092A2 (https=) |
| CA (1) | CA3098348A1 (https=) |
| DK (1) | DK3788042T3 (https=) |
| ES (1) | ES3018793T3 (https=) |
| FI (1) | FI3788042T3 (https=) |
| HR (1) | HRP20250392T1 (https=) |
| HU (1) | HUE071493T2 (https=) |
| IL (1) | IL278366B2 (https=) |
| LT (1) | LT3788042T (https=) |
| MX (2) | MX2020011495A (https=) |
| PL (1) | PL3788042T3 (https=) |
| PT (1) | PT3788042T (https=) |
| SG (1) | SG11202009933WA (https=) |
| SI (1) | SI3788042T1 (https=) |
| TW (1) | TWI855062B (https=) |
| WO (1) | WO2019210828A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3565815B1 (en) | 2017-01-07 | 2024-03-13 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| HUE060310T2 (hu) | 2017-04-18 | 2023-02-28 | Shanghai Fochon Pharmaceutical Co Ltd | Apoptosis-indukáló szerek |
| EP3737681A4 (en) | 2018-01-10 | 2022-01-12 | Recurium IP Holdings, LLC | BENZAMIDE COMPOUNDS |
| SI3788042T1 (sl) * | 2018-04-29 | 2025-06-30 | Beigene Switzerland Gmbh | Zaviralci BCL-2 |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021083135A1 (en) * | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
| KR20220100992A (ko) | 2019-12-06 | 2022-07-18 | 록쏘 온콜로지, 인코포레이티드 | 브루톤 티로신 키나제 억제제의 투여 |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| JP7839962B2 (ja) * | 2020-04-15 | 2026-04-03 | ビーワン メディシンズ ワン ゲーエムベーハー | Ｂｃｌ－２阻害剤 |
| EP4146649A4 (en) * | 2020-05-08 | 2024-09-11 | Fochon Biosciences, Ltd. | COMPOUNDS AS BCL-2 INHIBITORS |
| CN114478520B (zh) * | 2020-10-28 | 2025-01-10 | 杭州和正医药有限公司 | Bcl-2蛋白凋亡诱导剂及应用 |
| CN117642157A (zh) * | 2021-03-19 | 2024-03-01 | 伊尔治疗学股份有限公司 | 具有((3-硝基苯基)磺酰基)乙酰胺作为bcl-2抑制剂的化合物 |
| CN117616023A (zh) * | 2021-04-13 | 2024-02-27 | 爱新医药科技(香港)有限公司 | Bcl-2或bcl-2/bcl-xl调节剂及其用途 |
| EP4351542A4 (en) * | 2021-06-02 | 2025-04-09 | BeiGene Switzerland GmbH | Method for treating B-cell malignancy with BCL-2 inhibitor |
| CN115490708B (zh) * | 2021-06-18 | 2025-01-24 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
| CA3230314A1 (en) * | 2021-08-31 | 2023-03-09 | Beigene Switzerland Gmbh | Solid forms of bcl-2 inhibitors, method of preparation, and use thereof |
| WO2023078398A1 (en) * | 2021-11-05 | 2023-05-11 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
| US20250122191A1 (en) * | 2021-11-20 | 2025-04-17 | Fochon Biosciences, Ltd | Compounds as bcl-2 inhibitors |
| EP4442685A4 (en) * | 2021-12-06 | 2025-11-19 | Hangzhou Healzen Therapeutics Co Ltd | BCL-2 PROTEIN ANTI-APOPTOTIC INHIBITOR: PHARMACEUTICAL COMPOSITION AND USES |
| TW202400163A (zh) | 2022-05-12 | 2024-01-01 | 英屬開曼群島商百濟神州有限公司 | 使用ｂｃｌ－２抑制劑治療髓性惡性腫瘤之方法 |
| CN119365456A (zh) * | 2022-06-01 | 2025-01-24 | 重庆复创医药研究有限公司 | 作为bcl-2抑制剂的化合物 |
| CN119584963A (zh) * | 2022-07-21 | 2025-03-07 | 百济神州(苏州)生物科技有限公司 | 使用bcl-2抑制剂治疗多发性骨髓瘤的方法 |
| WO2024140690A1 (en) * | 2022-12-27 | 2024-07-04 | Beigene (Suzhou) Co., Ltd. | Intermediates of sonrotoclax and the method of preparing the same |
| AU2023416871A1 (en) * | 2022-12-27 | 2025-08-14 | Beone Medicines I Gmbh | Salts and solid forms of sonrotoclax intermediate |
| WO2024140678A1 (en) * | 2022-12-27 | 2024-07-04 | Beigene (Suzhou) Co., Ltd. | A ketal protected intermediate for sonrotoclax and preparation method thereof |
| WO2026002056A1 (en) | 2024-06-26 | 2026-01-02 | Beone Pharmaceutical (Suzhou) Co., Ltd. | A pharmaceutical formulation comprising solid dispersion of sonrotoclax and a process of preparation thereof |
| WO2026019442A1 (en) * | 2024-07-14 | 2026-01-22 | Eil Therapeutics, Inc. | Compounds having (3-nitrophenyl)acetamide as bcl-2 inhibitors |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US20020055631A1 (en) * | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| CA2577752A1 (en) | 2004-08-20 | 2006-03-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| EP1888550B1 (en) | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Apoptosis promoters |
| WO2006127364A1 (en) | 2005-05-24 | 2006-11-30 | Abbott Laboratories | Apoptosis promoters |
| CA2662320C (en) | 2006-09-05 | 2014-07-22 | Abbott Laboratories | Bcl inhibitors treating platelet excess |
| WO2009036051A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors containing a zinc binding moiety |
| CN102112445B (zh) | 2008-06-09 | 2014-06-18 | 百时美施贵宝公司 | 作为抗细胞凋亡Bcl抑制剂的羟基苯基磺酰胺 |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| UA108193C2 (uk) | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| HUE029289T2 (en) | 2008-12-05 | 2017-02-28 | Abbvie Inc | Sulfonamide derivatives as Bcl-2 selective apoptosis inducers for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| AU2009326259A1 (en) | 2008-12-08 | 2011-07-28 | Boehringer Ingelheim International Gmbh | Compounds for treating cancer |
| CN102282129A (zh) | 2009-01-19 | 2011-12-14 | 雅培制药有限公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| CN102282128B (zh) | 2009-01-19 | 2015-06-17 | Abbvie公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| NZ595708A (en) * | 2009-05-26 | 2014-03-28 | Abbvie Bahamas Ltd | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2011029842A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer |
| WO2011119345A2 (en) | 2010-03-25 | 2011-09-29 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| CA3152557A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| IT1403156B1 (it) | 2010-12-01 | 2013-10-04 | Università Degli Studi Di Torino | Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi. |
| SG192126A1 (en) | 2011-01-25 | 2013-09-30 | Univ Michigan | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
| CN103732589B (zh) | 2011-05-25 | 2016-03-30 | 百时美施贵宝公司 | 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺 |
| CN104039797B (zh) | 2011-10-12 | 2016-06-01 | 南京奥昭生物科技有限公司 | 作为细胞凋亡诱导剂的杂环分子 |
| EP2794592A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
| EP2794588A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
| MX2014007732A (es) | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los mismos componentes de enlace. |
| JP2015503518A (ja) | 2011-12-23 | 2015-02-02 | ノバルティス アーゲー | Ｂｃｌ２と結合相手の相互作用を阻害するための化合物 |
| BR112014015442A8 (pt) | 2011-12-23 | 2017-07-04 | Novartis Ag | compostos e composições para inibir a interação de bcl2 com parceiros de ligação |
| WO2013185202A1 (en) | 2012-06-14 | 2013-12-19 | Beta Pharma Canada Inc | Apoptosis inducers |
| KR102318204B1 (ko) | 2013-01-16 | 2021-10-26 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법 |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2017132474A1 (en) | 2016-01-30 | 2017-08-03 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| EP3481397A1 (en) | 2016-07-06 | 2019-05-15 | Concert Pharmaceuticals Inc. | Deuterated venetoclax |
| KR102376764B1 (ko) | 2016-08-05 | 2022-03-18 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물 |
| WO2018041248A1 (zh) | 2016-09-01 | 2018-03-08 | 北京赛林泰医药技术有限公司 | Bcl-2选择性抑制剂及其制备和用途 |
| CN106565706B (zh) | 2016-10-27 | 2018-05-01 | 广东东阳光药业有限公司 | 一种磺酰胺衍生物及其在药学中的应用 |
| CN106749233B (zh) * | 2016-11-24 | 2020-04-21 | 中山大学 | 一类磺酰胺衍生物及其应用 |
| EP3565815B1 (en) | 2017-01-07 | 2024-03-13 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| HUE060310T2 (hu) | 2017-04-18 | 2023-02-28 | Shanghai Fochon Pharmaceutical Co Ltd | Apoptosis-indukáló szerek |
| AU2018322059C1 (en) | 2017-08-23 | 2024-09-12 | Guangzhou Lupeng Pharmaceutical Company Ltd. | BCL-2 inhibitors |
| SI3788042T1 (sl) | 2018-04-29 | 2025-06-30 | Beigene Switzerland Gmbh | Zaviralci BCL-2 |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021110102A1 (en) | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
-
2019
- 2019-04-29 SI SI201930922T patent/SI3788042T1/sl unknown
- 2019-04-29 JP JP2020555218A patent/JP2021521138A/ja not_active Withdrawn
- 2019-04-29 AU AU2019264475A patent/AU2019264475C1/en active Active
- 2019-04-29 IL IL278366A patent/IL278366B2/en unknown
- 2019-04-29 EP EP19797052.8A patent/EP3788042B1/en active Active
- 2019-04-29 BR BR112020022092-2A patent/BR112020022092A2/pt unknown
- 2019-04-29 WO PCT/CN2019/085001 patent/WO2019210828A1/en not_active Ceased
- 2019-04-29 MX MX2020011495A patent/MX2020011495A/es unknown
- 2019-04-29 HU HUE19797052A patent/HUE071493T2/hu unknown
- 2019-04-29 EP EP25150254.8A patent/EP4545515A1/en active Pending
- 2019-04-29 CA CA3098348A patent/CA3098348A1/en active Pending
- 2019-04-29 US US17/050,581 patent/US11420968B2/en active Active
- 2019-04-29 SG SG11202009933WA patent/SG11202009933WA/en unknown
- 2019-04-29 HR HRP20250392TT patent/HRP20250392T1/hr unknown
- 2019-04-29 PT PT197970528T patent/PT3788042T/pt unknown
- 2019-04-29 CN CN202311486964.7A patent/CN117683029A/zh active Pending
- 2019-04-29 KR KR1020207033817A patent/KR102738032B1/ko active Active
- 2019-04-29 DK DK19797052.8T patent/DK3788042T3/da active
- 2019-04-29 LT LTEPPCT/CN2019/085001T patent/LT3788042T/lt unknown
- 2019-04-29 CN CN201980029015.1A patent/CN112437772B/zh active Active
- 2019-04-29 ES ES19797052T patent/ES3018793T3/es active Active
- 2019-04-29 CN CN202311185016.XA patent/CN117430601A/zh active Pending
- 2019-04-29 PL PL19797052.8T patent/PL3788042T3/pl unknown
- 2019-04-29 FI FIEP19797052.8T patent/FI3788042T3/fi active
-
2020
- 2020-04-28 TW TW109114185A patent/TWI855062B/zh active
- 2020-10-29 MX MX2023001689A patent/MX2023001689A/es unknown
-
2022
- 2022-05-23 US US17/750,821 patent/US12077536B2/en active Active
-
2024
- 2024-06-11 JP JP2024094048A patent/JP7540113B1/ja active Active
- 2024-06-17 US US18/745,423 patent/US20240376104A1/en active Pending
- 2024-08-14 JP JP2024135320A patent/JP7688210B2/ja active Active
-
2025
- 2025-05-22 JP JP2025085498A patent/JP2025119001A/ja active Pending